Taken together, our results showed that the significant correlation between subclonal ANK1 mutation, ANK1-driven genes and immune cell infiltration in CRC, suggesting subclonal ANK1 mutation as a prognostic marker plays potential role in immunotherapy for CRC. This evidence concerns the gene ANK1 and colorectal carcinoma.